Top Markets
#1 Islamic Coin Islamic Coin +151.50%
#2 DOVU DOVU +48.64%
#3 Akedo Akedo +46.30%
#4 Black Phoenix Black Phoenix +34.55%
#5 Velvet Velvet +32.25%
#6 DoubleZero DoubleZero +19.36%
#7 Cross Cross +16.34%
#8 Cap Cap +15.21%
#9 Tutorial Tutorial +13.37%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.43%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Classifica tra le azioni #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Prezzo delle azioni
$17.15
Ultima sincronizzazione: 2026-08-03
Capitalizzazione di mercato
$6.51M
Variazione (1 giorno)
9.80%
Variazione (1 anno)
289.77%
Paese
US
Scambia Galera Therapeutics, Inc. (GRTX)

Categoria

Healthcare
Rapporto P/S per Galera Therapeutics, Inc. (GRTX)
Rapporto P/S al August 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Galera Therapeutics, Inc., il rapporto P/S attuale (TTM) è 0.00. Alla fine del 2023, era pari a 0.00.
Storico del rapporto P/S per Galera Therapeutics, Inc. da 2017 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE